Sept 14 (Reuters) – Scholar Rock on Monday set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy that directly targets muscle loss in patients with the rare genetic disorder.
The net annual cost for a typical patient will be $310,000, but will vary depending on weight, the company’s executives said on a conference call.
(Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)
Comments